Stroke

New clinical trial results show LT3001's promise in treating acute ischemic stroke, demonstrating safety and improved patient outcomes without complications.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.

Andrew Russman, DO, medical director of Cleveland Clinic’s Comprehensive Stroke Center, shared insights on stroke awareness, prevention, and the growing importance of heart-brain collaboration in care.

Amid World Stroke Day, neurosurgeon Evan Luther, MD, discussed the PICASSO trial’s effort to clarify the role of acute carotid stenting during mechanical thrombectomy for tandem occlusions in ischemic stroke.

The chief science officer at the American Heart Association discusses its priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day 2025.

The co-director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute discussed decision-making for ruptured and unruptured aneurysm, endovascular and open outcomes, and training priorities for modern cerebrovascular care.

Portable optical blood flow monitors can enhance prehospital stroke diagnosis, enabling faster, accurate triage for large vessel occlusions and improving patient outcomes.

Semaglutide demonstrates superior cardiovascular benefits over dulaglutide, reducing heart attack and stroke risks in type 2 diabetes patients.

Grace Therapeutics reveals promising results for GTx-104, an innovative IV treatment for aSAH, potentially transforming patient care in neurocritical settings.

A recent trial reveals perispinal etanercept is safe for chronic stroke patients but shows no significant efficacy compared with placebo.

Novo Nordisk's semaglutide gains EU approval as the first oral GLP-1 RA to reduce cardiovascular risks in type 2 diabetes patients.

A recent study reveals GLP-1 receptor agonists significantly reduce medication use and symptoms in idiopathic intracranial hypertension patients, suggesting a promising management strategy.

Semaglutide significantly reduced the risk of heart attack, stroke, and death compared to tirzepatide in patients with obesity and cardiovascular disease.

Impaired kidney function significantly increases the risk of recurrent ischemic stroke, highlighting the need for tailored treatment strategies in high-risk patients.

Revalesio's RNS60 gains FDA fast track status, offering a groundbreaking approach to neuroprotection in ischemic stroke treatment.

At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonweath University discussed the rationale, results, and future directions of GLP-1 RA therapy as a novel treatment strategy for idiopathic intracranial hypertension.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a non-surgical option for idiopathic intracranial hypertension. [WATCH TIME: 3 minutes]

Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]

SECA, A randomized clinical trial of 155 patients with chronic subdural hematoma, showed that perioperative continuation of low-dose acetylsalicylic acid did not lower recurrence risk compared with placebo.

Helius reported promising results for its Portable Neuromodulation Stimulator, enhancing gait and balance in poststroke patients, with FDA submission planned.

Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.

The associate professor of neurology at Johns Hopkins detailed how artificial intelligence is shaping the future of neurology through its integration in clinical care, research, and medical education. [WATCH TIME: 4 minutes]

Nuri Jacoby, MD, a neurologist at Maimonides Medical Center and SUNY Downstate, previewed his talk at the 2025 AUPN Annual Meeting on using simulation to evaluate nonclinical competencies like communication and professionalism. [WATCH TIME: 3 minutes]

The professor of neurology at Albert Einstein College of Medicine talked about new findings presented at AHS, which suggested that both men and women with migraine can face significantly increased risks of ischemic stroke. [WATCH TIME: 5 minutes]